Drugs / OBI-902
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07124117 | Aug 2025 → Feb 2029 expected | neoplasm | OBI Pharma, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-12-05 | OBI Pharma, Inc | Regulatory OBI-902 Receives Consecutive FDA Orphan Drug Designation Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma obipharma.com ↗
OBI Pharma Inc. (4174.TWO) announced that its proprietarily developed TROP2-targeted antibody-drug conjugate (ADC), OBI-902, has received another Orphan Drug Designation (ODD) from the United States Food and Drug Administration (US FDA). |
| 2025-11-16 | OBI Pharma, Inc | Regulatory OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma. obipharma.com ↗
OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. |
| 2025-05-01 | OBI Pharma, Inc | Regulatory OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC obipharma.com ↗
OBI Pharma, Inc. （“OBI”）, a clinical stage oncology company （4174.TWO）, today announced that the U.S. Food and Drug Administration （FDA） has cleared an investigational new drug （IND） application for OBI-902, to conduct a Phase 1/2 study. |
| 2025-04-23 | OBI Pharma, Inc | Results OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science. obipharma.com ↗
OBI-902 demonstrated superior antitumor activity and favorable PK/PD properties compared to benchmark TROP2 ADCs across various animal models. |
All press releases naming this drug 5 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBI-902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07124117 ↗ |